Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02743897 · ClinicalTrials.gov registry record · Phase 1

Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients

A Phase 1 study, sponsored by University of Pennsylvania.

Completed
Registry status
Phase 1
Development phase
62
Enrollment target

NCT02743897: Completed Phase 1 study, sponsored by University of Pennsylvania.

NCT02743897 is a Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 62 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02743897, a Phase 1 study, has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
Phase 1
Development phase
62 participants
Enrollment target

Study Summary

This study is being conducted to determine safety and effectiveness of transplanting kidneys from Hepatitis C-positive donors into Hepatitis C-negative patients on the kidney transplant waitlist, who will then be treated with the appropriate direct-acting antiviral (DAA) after the single kidney transplantation.

Interventions

  • DRUG Mavyret
  • DRUG Zepatier

Trial Details

FieldValue
Enrollment Target 62 participants
Start Date 2016-05-01
Est. Completion 2022-12
Phase Phase 1

Sponsor

University of Pennsylvania

1,423 total trials

What the Registry Record Tells You About NCT02743897

The ClinicalTrials.gov registry entry for NCT02743897 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Mavyret is the first listed.

NCT02743897 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02743897 about?

NCT02743897 is a clinical study titled "Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients". This study is being conducted to determine safety and effectiveness of transplanting kidneys from Hepatitis C-positive donors into Hepatitis C-negative patients on the kidney transplant waitlist, who will then be treated with the appropriate direct-acting antiviral (DAA) after the single kidney tran...

What is the current status of trial NCT02743897?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2016-05-01. Estimated completion is 2022-12.

What interventions are being tested in trial NCT02743897?

The interventions under investigation include: Mavyret (DRUG), Zepatier (DRUG).

Who is sponsoring clinical trial NCT02743897?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.